A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Trial Profile

A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs IMC CS4 (Primary) ; Cobimetinib; Vemurafenib
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 10 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top